肺癌生存率的国际差异:按性别、组织学类型和诊断分期分析
结果显示加拿大和挪威生存率较高,英国、新西兰和爱尔兰较低;女性生存率高于男性,部分因男性诊断时分期更晚。同一分期内仍存在国际差异,提示治疗质量、医疗系统因素和合并症患病率等可能影响生存。
要点
- 加拿大和挪威肺癌净生存率较高,英国、新西兰和爱尔兰较低。
- 女性NSCLC和SCLC生存率均高于男性,部分因男性诊断分期更晚。
- 同一分期内仍存在国际生存差异,提示治疗和系统因素的作用。
核心结论
- 肺癌诊断分期分布因性别、组织学亚型和国家而异,可部分解释观察到的生存差异。
- 同一分期内仍存在生存差异,提示治疗质量、医疗系统因素和合并症患病率等可能也影响生存。
- 其他可能解释包括数据收集实践、组织学验证、分期和编码的跨辖区差异。
研究设计与样本
- 按性别、组织学类型、分期和国家估计1年和3年年龄标化净生存率。
主要发现
- NSCLC的3年净生存率男性从英国19.7%到加拿大27.1%,女性从英国25.3%到加拿大35.0%。
- SCLC的3年净生存率女性最高为加拿大13.8%、挪威12.8%,男性最高为挪威9.7%、加拿大9.1%。
- NSCLC生存率的国际差异在区域期最大,在晚期最小。
- 加拿大和挪威的1年和3年净生存率 consistently 较高,英国、新西兰和爱尔兰较低,无论诊断分期如何。
临床怎么用
- 临床应关注肺癌诊断分期分布的人群差异,尤其是男性更晚分期对生存的影响。
- 同一分期内的生存差异提示需关注治疗质量、医疗系统因素和合并症管理。
局限性
- 数据收集实践、组织学验证、分期和编码的跨辖区差异可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer has a poor prognosis that varies internationally when assessed by the two major histological subgroups (non-small cell (NSCLC) and small cell (SCLC)). METHOD: 236 114 NSCLC and 43 167 SCLC cases diagnosed during 2010-2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK were included in the analyses. One-year and 3-year age-standardised net survival (NS) was estimated by sex, histological type, stage and country. RESULTS: One-year and 3-year NS was consistently higher for Canada and Norway, and lower for the UK, New Zealand and Ireland, irrespective of stage at diagnosis. Three-year NS for NSCLC ranged from 19.7% for the UK to 27.1% for Canada for men and was consistently higher for women (25.3% in the UK; 35.0% in Canada) partly because men were diagnosed at more advanced stages. International differences in survival for NSCLC were largest for regional stage and smallest at the advanced stage. For SCLC, 3-year NS also showed a clear female advantage with the highest being for Canada (13.8% for women; 9.1% for men) and Norway (12.8% for women; 9.7% for men). CONCLUSION: Distribution of stage at diagnosis among lung cancer cases differed by sex, histological subtype and country, which may partly explain observed survival differences. Yet, survival differences were also observed within stages, suggesting that quality of treatment, healthcare system factors and prevalence of comorbid conditions may also influence survival. Other possible explanations include differences in data collection practice, as well as differences in histological verification, staging and coding across jurisdictions.
引用
- Araghi M, Fidler-Benaoudia M, Arnold M, et al. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study. Thorax. 2021. PMID: 34282033. doi:10.1136/thoraxjnl-2020-216555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。